ClinicalTrials.gg
TerminatedNCT05993143Updated Aug 15, 2023

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50

A Phase 3 interventional study of Ivermectin and Placebo in COVID-19 and SARS-CoV-2, sponsored by Insud Pharma. Terminated at 20 sites in Spain. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by Insud Pharma · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was stopped because no statistically significant difference was observed in the interim analysis. With high vaccine rates in those over 50 and an expected low incidence, it would not be feasible to complete recruitment within a short period.

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Jan 2021, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing ivermectin in COVID-19 — 2 open to participants now, 2 under way, 1 of them phase 3. Ivermectin · COVID-19.

Enrollment
24th of 55
249 · median 180
Started
2021
with 17 others
Phase 3
17 of 55
1 open now
Registered
55th of 55
by date

Among the 55 studies testing ivermectin in COVID-19, this one is the 24th largest by enrollment, is one of 18 that started in 2021, is one of 17 in phase 3, and was the 55th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 55 studies testing ivermectin in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing ivermectin in COVID-19, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 hospitalisation in adults older than 50 years of age. Secondary objectives include assessing the efficacy of an early administration of ivermectin for three consecutive days to prevent SARS-CoV-2 disease progression in adults older than 50 years of age and evaluating the safety and tolerability of ivermectin in SARS-CoV-2 infected adults older than 50 years of age.

Read the detailed description

This is a randomised, double-blind, placebo-controlled, multicentre trial in parallel groups. During the screening/enrollment phase (Visit 1.1 to Visit 1.3) informed consent will be obtained and the screening procedures will be performed. A rapid antigen-based test will be offered to all patients who do not have a polymerase chain reaction (PCR) or a rapid antigen-based test result at screening (each of these tests may be considered a part of the standard procedure of the site). Eligible subjects will be randomised 1:1 to receive ivermectin or placebo. The subjects will be dispensed investigational product (IP), based on their body weight, and will take the first dose of IP at site. The subjects will receive portable pulse oximeters for peripheral capillary oxygen saturation (SpO2) monitoring at home. The treatment phase will last 3 days and include an on-site Visit 1.3 and phone call Visits 2 and 3 which will be performed on the following 2 days. PCR test or rapid antigen test results will be communicated to subjects as soon as available. Subjects with negative COVID-19 PCR test or rapid antigen test results will be withdrawn from the trial unless they have a positive rapid antigen test or COVID-19 PCR test result a few days later. The subjects will be followed up until Day 28.

During the follow-up, the subjects will have phone call Visits 4 to 9 every other day, followed by Visit 10 after one week (Day 21). The subjects will be asked to measure oxygen saturation as well as body temperature during all phone call visits and report the respective results to the investigator. The on-site Visit 11 is the last visit (Day 28). The subjects will return IPs (including empty and partially empty containers) and pulse oximeters.

In addition, the subjects will be provided with a contact number available 24/7 to contact the investigator if their condition worsens. In case of health condition worsening (dyspnoea, fever [body temperature ≥ 37.8°C] lasting for more than 6 days, SpO2 ≤ 95% or any other worsening criteria based on the investigator's judgement) confirmed during the phone call visit, the subjects will have an unscheduled visit at the site.

The subjects will be hospitalised if they fulfill any of the following criteria: pneumonia confirmed by chest X-ray; SpO2 ≤ 94% or partial pressure of oxygen in blood (PO2) \< 80 mmHg in gasometry; respiratory frequency > 20 rpm; fever (body temperature ≥ 37.8°C) for more than 6 days plus one of the following analytic parameters: C-reactive protein (CRP) > 5 mg/dL, ferritin > 500 ng/mL or D dimer > 700 ng/mL. If there is any other condition that requires hospitalisation as per investigator judgement, the condition has to be documented in detail in the subject's file including a description whether the hospitalisation was performed due to SARS-CoV-2 infection.

03

Conditions studied

  • COVID-19
  • SARS-CoV-2

Browse trials for

Keywords

  • ivermectin
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult > 50 years of age
  2. SARS-CoV-2 infection diagnosed either through a rapid antigen-based test or an RNA based reverse-transcription polymerase chain reaction (RT-PCR) diagnostic test performed in nasopharyngeal sample
  3. Onset of COVID-19 symptoms \< 120 hours (5 days) prior to screening
  4. Written
  5. For females of only: They must declare that they did not intend to become pregnant in the last month prior to screening and they do not intend to become pregnant for one month following the last IP administration. For males who have partners of childbearing potential: Willing to use condoms until 3 months after last IP intake.
  6. Negative result for urine pregnancy test (women of childbearing potential only)

Exclusion criteria

Exclusion Criteria:

  1. Intake of Ivermectin within 30 days before screening
  2. Routine intake of antivirals, including antiretroviral treatment
  3. Allergy, or to Ivermectin, metabolites or
  4. Subjects with symptoms of disease severity (dyspnoea, SpO2 ≤ 94%)
  5. Subjects requiring hospitalisation for any reason.
  6. Epidemiological risk or suspicion of being infected by Loa loa or other filariases
  7. Previous enrolment in this trial or participation in any other drug trial within the past 30 days (or five half-lives of IP whichever is longer) prior to screening
  8. Weight \< 50 kg
  9. Pregnancy or lactation
  10. Inability to take oral medications
  11. At least one of the following acute/chronic disease or deficiency:

    1. History of bone marrow transplant or haematopoietic systems diseases
    2. Moderate or severe liver disease ( score ≥ B or [alanine transaminase] or AST [aspartate transaminase] > 3 times upper limit as determined at screening visit), severe cholestasis, cirrhosis or severe hepatic failure
    3. Transplanted patient under treatment, disease that may need immunosuppressive treatments or other medical conditions that under the judgement of investigator would not benefit the patient to be included (including but not limited to psoriasis, G6PD (glucose-6-phosphate dehydrogenase) deficiency, porphyria, history of diverticulosis, seizure disorder, concurrent requiring chemotherapy, ongoing skin infection (e.g. pyodermitis) or evidence of current tuberculosis including latent untreated tuberculosis)
    4. Ophthalmological or recent/ongoing neurological diseases
  12. Active cardiac disease or a history of cardiac dysfunction including any of the following:

    1. History of angina pectoris, symptomatic pericarditis, or myocardial infarction within 12 months prior to screening
    2. History of congestive heart failure ( functional classification III-IV)
  13. Concomitant use of barbiturates, sodium oxybate, valproic acid or warfarin
  14. Laboratory abnormalities relevant for the trial, including but not limited to: neutropenia \< 500/mm3, thrombocytopenia \< 100,000/mm3
  15. Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the subject because of participation in the study, affect the ability of the subject to participate in the study or impair interpretation of the study data
  16. Employees of the investigator or clinical trial site, with direct involvement in the proposed trial or other studies under the direction of that investigator or clinical trial site, as well as family members of the employees or the principal investigator
  17. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    Ivermectin (test product)

    Ivermectin 9 mg and 18 mg immediate-released tablets to be taken orally once daily during 3 days at 600 µg/kg/day ± 120 µg/kg/day depending on their body weight.

    Drug: Ivermectin

  • Placebo comparator
    Placebo (reference product)

    Placebo tablets to be taken orally once daily during 3 days.

    Drug: Placebo

Interventions

  • Round and white tablets

    Also known as: Ivermectin 9 mg and 18 mg

  • DrugPlacebo

    Round and white tablets

06

What researchers measure

Primary outcomes

  1. Hospitalisation due to SARS-CoV-2

    Percentage of subjects requiring SARS-CoV-2 hospitalisation during 28 days after first IP administration.

    Time frame: day 1 to day 28

Secondary outcomes

  1. Change in subjects' clinical status

    Efficacy of an early administration of Ivermectin for three consecutive days to prevent SARS-CoV-2 disease progression in adults older than 50 years of age.

    Time frame: day 1, 2, 3, 4, 6, 8, 10, 12, 14, 21 and 28

  2. Occurrence of any adverse event related to Ivermectin treatment

    Evaluation of safety and tolerability of Ivermectin in SARS CoV 2 infected adults older than 50 years of age

    Time frame: day 1, 2, 3, 4, 6, 8, 10, 12, 14, 21 and 28

07

Study locations

20 sites
  • Hospital de Poniente
    El Ejido, Almeria 04700, Spain
  • Hospital Universitari Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital General de Granollers
    Granollers, Barcelona 08402, Spain
  • Hospital San Pedro
    Logroño, La Rioja 26006, Spain
  • HM Montepríncipe
    Boadilla del Monte, Madrid 28660, Spain
  • HM Puerta del Sur
    Móstoles, Madrid 28938, Spain
  • HM Torrelodones
    Torrelodones, Madrid 28250, Spain
  • Clínica Universidad de Navarra
    Pamplona, Navarra 31008, Spain
  • Complejo Hospitalario Universitario A Coruña-CHUAC
    A Coruña, 15006, Spain
  • Centro de Atención Primaria Les Corts
    Barcelona, 08028, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08041, Spain
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
  • Clínica Universidad de Navarra - Madrid
    Madrid, 28027, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • HM Sanchinarro
    Madrid, 28050, Spain
  • Complejo Hospitalario de Navarra
    Pamplona, 31008, Spain
  • Complejo Asistencial Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Virgen de la Macarena
    Sevilla, 41009, Spain
  • Hospital Universitari de Tarragona Joan XXIII
    Tarragona, 43005, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Jul 2021, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2023
First posted
Aug 15, 2023
StartActual
Jan 18, 2021
Primary completionActual
Jul 21, 2021
CompletionActual
Jul 21, 2021
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05993143
Lead sponsor
Insud Pharma
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Jan 18, 2021
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Last update
Aug 15, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion